CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

NCT ID: NCT07008872

Last Updated: 2025-06-06

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-01
• Study Completion Date: 2027-05-31

Brief Summary

CD7 molecules are thought to be associated with disease aggressiveness, drug resistance, and poor prognosis. Intensive chemotherapy, immunotherapy, hematopoietic stem cell transplantation (HSCT) and other treatment regimens have achieved remarkable results in the treatment of hematologic malignant diseases. Nevertheless, patients with hematologic malignancies may still tolerate acquired therapy during the above treatments, and molecular targeted immunotherapy provides a safe, efficient and specific treatment for such patients The scheme has attracted more and more researchers' attention. The use of CD7 molecules as a new target for molecularly targeted anti-tumor therapy may provide a new research direction for the treatment of CD7 relapsed/refractory hematologic malignancies.

Conditions

CD7+ Lymphoma; CD7+ Acute Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CD7 CAR-T

For intravenous infusion

Group Type: EXPERIMENTAL

CD7 CART

Intervention Type: BIOLOGICAL

For intravenous infusion

Interventions

CD7 CART

For intravenous infusion

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Subjects must meet all of the following criteria to be enrolled:

1. Subjects diagnosed with relapsed/refractory lymphoma/leukemia:

1. Relapsed/refractory T-cell malignant lymphoma: patients who have not remission and recurrence after at least 2 courses of standardized second-line or above treatment (including hematopoietic stem cell transplantation).

2. Relapsed/refractory T-cell acute lymphocytic or myeloid leukemia meeting any of the following criteria:

i) Relapse: After achieving complete remission with a standard treatment regimen (including hematopoietic stem cell transplantation), blasts appear in peripheral blood or bone marrow (proportion>5%), or extramedullary diseases occur; ii) Refractory: No complete remission after at least two courses of standard induction therapy.

2. Bone marrow flow cytometry detected tumor cells as CD7 and/or extramedullary lesions with a clear diagnosis of CD7 by pathological immunohistochemistry at the time of enrollment screening;

3. If tumor cells are detected in peripheral blood during enrollment screening, flow cytometry must be used to detect that the immunophenotype of tumor cells on the surface of tumor cells is both negative for CD4 and CD8. If the immunophenotype on the surface of peripheral blood tumor cells is not CD4 and CD8 negative, the proportion of peripheral blood tumor cells must be ≤1%;

4. Expected survival greater than 3 months from the date of signing the informed consent form;

5. Subjects with a performance status of 0~2 in the Eastern Cooperative Oncology Group (ECOG) score;

6. 14 years old≤ age ≤ 75 years old, male or female;

7. HGB at least ≥70g/L, blood transfusion is available;

8. Liver and kidney function, heart and lung function meet the following requirements:

1. creatinine ≤1.5×ULN;

2. left ventricular ejection fraction ≥50%;

3. Oxygen saturation >90%;

4. Total bilirubin ≤1.5×ULN; ALT and AST ≤2.5×ULN;

9. Subject or guardian understands and signs the informed consent form.

Exclusion Criteria

1. One of the following cardiac criteria occurs: atrial fibrillation; Myocardial infarction within the past 12 months; Prolonged QT syndrome or secondary QT Extension, to be determined by the researcher. Echocardiography with LVSF<30% or LVEF<50%; Clinically significant pericardial effusion; Heart function Incomplete NYHA III or IV (confirmed by echocardiography within 12 months after treatment);

2. Active GVHD;

3. Have a history of severe pulmonary dysfunction;

4. Merge other advanced malignant tumors;

5. Combination of severe or persistent infections that cannot be effectively controlled;

6. Combination of severe autoimmune diseases or congenital immunodeficiency;

7. Active hepatitis (hepatitis B virus deoxyribonucleic acid [HBV-DNA ≥ 500 IU/ml and abnormal liver function] or anti hepatitis C virus Positive for HCV Ab, HCV-RNA above the detection limit of the analytical method, and abnormal liver function;

8. Human immunodeficiency virus (HIV) infection or syphilis infection;

9. Have a history of severe allergies to biological products (including antibiotics);

10. There are central nervous system disorders, such as uncontrolled epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, etc;

11. Female patients who are pregnant or breastfeeding, or have a pregnancy plan within 12 months;

12. The researcher believes that there may be situations that increase the risk to the subjects or interfere with the test results.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

Sponsor Role: collaborator

Qi deng

OTHER

Sponsor Role: lead

Responsible Party

Qi deng

Chief Physician

Responsibility Role: SPONSOR_INVESTIGATOR

Other Identifiers

XB-20240912-1

Identifier Type: -

Identifier Source: org_study_id